GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Forward PE Ratio

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Forward PE Ratio : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Forward PE Ratio?

Paradigm Biopharmaceuticals's Forward PE Ratio for today is 0.00.

Paradigm Biopharmaceuticals's PE Ratio without NRI for today is 0.00.

Paradigm Biopharmaceuticals's PE Ratio for today is 0.00.


Paradigm Biopharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Forward PE Ratio Chart

Paradigm Biopharmaceuticals Annual Data
Trend
Forward PE Ratio

Paradigm Biopharmaceuticals Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Paradigm Biopharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Forward PE Ratio falls into.



Paradigm Biopharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Paradigm Biopharmaceuticals  (OTCPK:PBIGF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Paradigm Biopharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Headlines

From GuruFocus